
    
      (1ï¼‰To find out the differences of expression of mRNA, lncRNA, miRNA and proteins of PRKCB1
      between patients with depressive disorder and healthy subjects.

      (2) Patients with depressive disorders will be randomized into two groups that they will be
      treated with escitalopram or escitalopram plus Omega-3 PUFAs. To observe the effects of
      Omega-3 PUFAs on PRKCB1 and related neuroimmune/neuroinflammatory pathway which may improve
      understanding the relationship between neuroinflammatory regulation and depressive disorder
      treatment.
    
  